Patents
Literature
9 results about "ERBB3" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Receptor tyrosine-protein kinase erbB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane bound protein that in humans is encoded by the ERBB3 gene. ErbB3 is a member of the epidermal growth factor receptor (EGFR/ERBB) family of receptor tyrosine kinases. The kinase-impaired ErbB3 is known to form active heterodimers with other members of the ErbB family, most notably the ligand binding-impaired ErbB2.
Humanised sequence for the generation of Anti-ERBB3 / her3 antibodies
PCT designated stageWO2026088233A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsTyrosineIntravenous gammaglobulin
The present invention relates to a humanised sequence binding the receptor tyrosine kinase ErbB3 / HER3 for the generation of anti-ErbB3 / HER3 antibodies in different formats, such as, for example, immunoglobulins, bispecific antibodies, in particular bispecific T-cell engagers, or antibody-drug conjugates (ADCs) or fusion immunoproteins, for the treatment of solid tumours depending on the expression of the ErbB3 receptor.
Owner:TAKIS
Composition for preventing or treating brain disorders
Disclosed is a pharmaceutical composition for preventing or treating a brain disease, containing as an active ingredient an ErbB3-binding protein 1 (EBP1) protein or a polynucleotide sequence encoding the EBP1 protein, wherein an EBP1 N84A / N204A protein, which is an EBP1 mutant in an asparagine endopeptidase (AEP)-uncleavable form, and a polynucleotide encoding the same can reduce amyloid beta production and enhance cognitive function in the early stages of Alzheimer's disease, and thus the composition can be advantageously used as a therapeutic agent for brain diseases including sporadic Alzheimer's disease.
Owner:RES & BUSINESS FOUND SUNGKYUNKWAN UNIV
Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated NRG1 expression
The invention relates to the field of ErbB-2 and / or ErbB3 targeting agents, such as antibodies binding ErbB-2 and / or ErbB3. In particular it relates to the field of therapeutic (human) antibodies for the treatment of a ErbB-2 / ErbB-3 positive cell, tumor or cancer. More in particular it relates to treating malignant cells, tumors or cancers comprising high NRG1 expression levels.
Owner:MERUS NV
Means and methods for treating castration-resistant prostate cancer
The present invention relates to means and methods for treating castration-resistant prostate cancer. The present invention relates to the field of therapeutic antibodies for use in the treatment of individuals with castration-resistant prostate cancer. More specifically, the present invention relates to the treatment of castration-resistant prostate cancer using a bispecific antibody comprising an antigen binding site that can bind to an extracellular portion of ERBB2 and an antigen binding site that can bind to an extracellular portion of ERBB3. In addition, the present invention relates to the treatment of castration resistant prostate cancer using an antibody comprising an antigen binding site that can bind to an ERBB3 extracellular portion. The invention also relates to the treatment of castration resistant prostate cancer using a combination of one of the antibodies and an androgen receptor axis-targeting agent.
Owner:MERUS NV
Neuregulin-1 / Anti-her3 antibody fusion protein for use in the treatment of heart failure
PCT designated stageWO2025245112A1Peptide/protein ingredientsNeuregulinsNeuregulinAntiendomysial antibodies
Provided herein are recombinant fusion proteins comprising an active fragment of neuregulin-1 (NRG-1) fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb), and methods of using same to treat cardiovascular disease.
Owner:SALUBRIS BIOTHERAPEUTICS INC
Means and methods for treating castration-resistant prostate cancer
PendingUS20260167740A1Organic active ingredientsAntibody ingredientsAntiendomysial antibodiesBinding site
The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.
Owner:MERUS NV
AN ERBB3 BINDING SPECIFIC ANTIBODIES AND USE OF THEM
ActiveDE602016094833T2Organic active ingredientsAntibody ingredientsAntiendomysial antibodiesBiochemistry
Owner:ISU ABXIS
Anti-ERBB3 antibodies or their antigen-binding fragments and their pharmaceutical uses
This relates to anti-ERBB3 antibodies or their antigen-binding fragments and their pharmaceutical uses, particularly to fully human antibodies against the ERBB3 receptor or their antigen-binding fragments and their pharmaceutical uses. It also includes pharmaceutical compositions comprising fully human anti-ERBB3 antibodies or their antigen-binding fragments, and their use as anticancer drugs.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1
Anti-ERBB3 antibodies
ActiveUS12486332B2Peptide/protein ingredientsImmunoglobulins against growth factorsDiseaseAntiendomysial antibodies
Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3 / HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3 / HER3.
Owner:AVEO PHARMACEUTICALS INC